CD274 and neoplasm: Interestingly, patients benefited from pembrolizumab regardless of PD-L1 expression, measured as the combined positive score (CPS), defined as the proportion of PD-L1-expressing tumor and infiltrating immune cells relative to the total number of tumor cells.